Chimerix (CMRX) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Chimerix (CMRX) Tops Q1 EPS by 3c

Chimerix Announces First Quarter Financial Results

May 11, 2015 7:30 AM EDT

DURHAM, N.C., May 11, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the first quarter 2015.

M. Michelle Berrey, MD, MPH, President and CEO of Chimerix, said, "The first quarter of 2015 allowed us to make significant progress in our development program for brincidofovir. We are close to completing enrollment of our Phase 3 SUPPRESS trial for the prevention of cytomegalovirus (CMV) in stem cell transplant recipients. We continue to rapidly enroll patients in our Phase 3 AdVise study for the... More